Introduction: 

• It is a clonal MPN characterized by proliferation of mainly megakaryocytic and granulocytic elements in bone marrow, associated with reactive deposition of bone marrow connective tissue and extra medullary erythropoiesis. 

Epidemiology: 

• Incidence – 0.5 – 1.5 / 1 lac population
• Commonly seen at around 70 years of age
• May be seen in infants with autosomal recessive inheritance 

Etiology: Exact cause is not known

• Radiation
• Exposure to benzene
• Familial myelofibrosis
• Immune mechanisms- Higher incidence of MF is seen in patients with SLE 
• Acquired mutations 
  • Activating mutations of JAK/STAT pathway
    • JAK2V617F is seen in 65% of cases. Exon 12 mutation is infrequent 
    • CALR mutation- Seen in 25-35% patients
    • Myeloproliferative leukemia virus (MPL)- Thrombopoietin receptor gene on 1p34 Exon 10- (MPLW515L/K)- Seen in 5-10% cases 
  • Ten-eleven translocation 2 (TET-2)- 4q24- Seen in 17% cases 
  • Enhancer of Zeste homolog 2 (EZH2)- 7q36.1- Seen in 13% cases 
  • Casitas B Lineage Lymphoma (CBL)- 11q 23.3 Exons 8 and 9- Seen in 6% cases 
  • Isocitratedehydrogenase (IDH)- 1 and 2- 2q33.3/15q 26.1- Seen in 4% cases 
  • Ikaros Family Zinc Finger 1 (IKZF1)- 7p12- Infrequent 
  • Additional sex combs like 1 (ASXL1)- 20q11- Infrequent 
  • Other mutations include: DNMT3A, 

Pathogenesis: 

1.

Hyperactivation of thrombopietin/MPL/JAK2 axis

and

Down-regulation of GATA1 expression

↓

Defective package of growth factors such as PDGF, Fibroblast growth factor, MMP9 and TGF beta in neoplastic megakaryocytes

↓

Inappropriate release of these growth factors

↓

These factors diffuse into intercellular milieu

↓

Proliferation of fibroblasts and neovascularization due to proliferation of capillaries

Fibroblasts are not clonal; hence they are not tumor cells. But hematopoietic cells are.

2.

Epigenetic Methylation of CXCR4 promoters

↓

Decreased CXCR4 mRNA

↓

Decreased CXCR4 expression on CD34+ cells

↓

Enhanced migration of CD34+ cells in blood (These cells have predisposition to differentiate into megakaryocytes)

3.

Increase in circulating endothelial cell progenitors + Release of EGFbeta, BFGF and VEGF from megakaryocytes

↓

Increased angiogenesis

4.

Over-expression of FKBP51 on megakaryocytes

↓

Resistance to apoptosis through calcineurin pathway

5.

Increased number of CD34+ cells exit from BM

↓

Filtered in spleen due to abnormal trafficking pattern

↓

Accumulate progressively and continue to proliferate

↓

Extramedullary hematopoiesis (myeloid metaplasia) and splenomegaly

• Functional abnormalities of neutrophils: Impaired phagocytosis, oxygen consumption, nitro blue tetrazolium reduction, hydrogen peroxide generation, decreased myeloperoxidase. 
• Platelet abnormalities: Impaired aggregation with epinephrine, depletion of dense granules adenosine diphosphatase content, decreased platelet lipo-oxygenase pathway 

Clinical Features: 

• Prefibrotic phase- Asymptomatic without any organomegaly. CBC may show mild anemia, mild leucocytosis and/or thrombocytosis. (Close differential diagnosis is ET. In ET megakaryocytes although increased do not show dysmorphia. Follow up usually clarifies the diagnosis) 
• Fibrotic phase: 
  • Hypercatabolic state: Low grade fever, night sweats, fatigue, weight loss, Pruritus
  • Anemia
  • Splenomegaly – Massive. Often leads to early satiety.
  • Hepatomegaly – Slight to moderate, firm, smooth non tender
  • Bleeding manifestations due to thrombocytopenia
  • Thromboembolism- Venous/ arterial
  • Bone pain

Complications: 

• Bone marrow failure leading to frequent infections and hemorrhage
• Portal hypertension due to
  • Extramedullary hematopoiesis in liver 
  • Massive increase in hepatic blood flow and intrahepatic obstruction. 
  • Perisinusoidal fibrosis 
  • Collagen bundles in space of Disse 
• Cardiac failure due to anemia
• Leukemic transformation – Seen in 20-25% patients
• Development of PNH clone
• Acquired HbH disease
• Pure red cell aplasia 
• Pulmonary hypertension
• Nephrotic syndrome 
• Mass of extramedually hematopoiesis- Pulmonary, GI, CNS, genitourinary 
• Neutrophilic dermatosis (Sweet's syndrome)- which can progress to bullae/ pyodermagangrenosum 
• Leukemia cutis- Larger cells are seen which are CD61 positive 

Investigations:

• Hemogram
  • Prefibrotic phase: 
    • No or mild leukoerythroblastosis 
    • No or minimal red blood cell poikilocytosis; few if any dacrocytes 
    • Mild anemia 
    • Mild to moderate leucocytosis 
    • Mild to marked thrombocytosis 
  • Fibrotic phase
    • Normocytic normochromic anemia, prominent red blood cell poikilocytosis with  dacrocytes (Tear drop cells) 
    • Leucocytosis with TLC usually between 10,000-14,000/cmm, with blasts <10%./ Leucopenia 
    • Leucoerythroblastic blood picture- Plenty of nRBCs with shift to left in myeloids up to blasts 
    • Slight basophilia 
    • Thrombocytosis/ thrombocytopenia. 
    • Giant platelets with abnormal platelet granulation. 
    • Pancytopenia is noted in 10% of cases. 
• Bone Marrow : 
  • Prefibrotic phase
    • Hypercellularity 
    • Neutrophilic proliferation 
    • Megakaryocytic proliferation and atypia (clustering of  megakaryocytes, hyperchromatic and abnormally lobulated or cloud like megakaryocytic nuclei, naked megakaryocytic nuclei) 
    • Minimal or absent reticulin fibrosis. If present it tends to be concentrated around blood vessels. 
    • Erythropoiesis is reduced 
  • Fibrotic phase: 
    • Aspirate is generally a dry tap. 
    • Increased cellularity- Hypercellular fragments and hypocellular trails 
    • Biopsy shows extensive fibrosis
    • Dilated marrow sinuses with intraluminal hematopoiesis 
    • Prominent megakaryocytic proliferation and atypia (clustering of megakaryocytes, abnormally lobulated megakaryocytic nuclei. Dense chromatin clumping, nuclear hyperchromasia, bulbous/ cloud like nuclear lobes and naked nuclei are seen) 
    • Increased number of dysmorphic megakaryocytes are seen, even in fibrotic areas. 
    • Increased pathologic emperipolesis- Entry of neutrophils and other marrow cells into canalicular system of megakaryocyte. (This is also responsible for alfa granule injury and release of TGF beta and PDGF) 
    • Erythropoiesis- Suppressed 
    • Granulocytic hyperplasia 
    • Reticulin and/or collagen fibrosis of varying degrees is seen (Usually MF-2 to MF-3)
    • New bone formation (osteosclerosis) 
    • Grading of fibrosis

 
Fibrotic stroma is rich in Type 1 and 3 collagen. Reticulin stain principally stains type 3 collagen. Thick fibers with type 1 collagen stain with trichrome stain. Hence this stain is positive only in advanced disease. 

Accelerated phase of PMF - 10-19% blasts seen in blood or marrow 

Blast phase of PMF - ≥20% blasts in blood or bone marrow

• ESR-Elevated 
• Neutrophil alkaline phosphatase score-Raised
• Serum uric acid level-Raised
• Serum LDH level – Raised
• Serum folate level – Decreased (Due to utilization by abnormal tissue)
• X-Ray of bone 
  • Patchy sclerosis of medullary cavity
  • Coarsening of trabeculation
  • Rarefaction giving mottled appearance 
• MRI 
  • New bone formation and periosteal thickening
  • Altered hyperintensity of T1 weighted images that normally result from marrow fat 
• Lumbar spine dual energy X ray absorption and quantitative CT 
  • Increased bone formation 
  • Bone thickening 
  • Increasedcancellous and woven bone 
  • Rarely osteolytic lesions 
• Immunophenotyping- Nothing specific 
• Immunohistochemistry:
  • CD34 and CD117: help in enumerating number of blasts
  • CD61 and CD42b: Highlight megakaryocytes
  • CAL2 is positive in megakaryocytes if CALR is mutated.
• Cytogenetics – 
  • Nothing specific.
  • Seen in 45% patients. 
  • Common abnormalities: del (13q) , del (20q), partial trisomy 1q,  +8, +9 
  • Abnormalities associated with poor prognosis: Complex karyotype, inv (3), monosomy 5 or del (5q), monosomy 7 or del (7q), del 12p, 11q23 rearrangement, and i(17q)
• Molecular tests for MPN related mutations- BCR-ABL1, JAK 2, CAL R and MPL.
• Peripheral blood CD 34 cell count- Increased 
• Mutations of N-RAS, C-KIT and p53

Criteria for Diagnosis: 

• Prefibrotic/Early stage:  requires that all 3 major criteria and at least 1 minor criterion (Minor criteria must be metwhich is confirmed in 2 consecutive determinations).
  • Major criteria
    • Megakaryocytic proliferation and atypia, without reticulin fibrosis/ grade 1 fibrosis accompanied byincreased age-adjusted bone marrow cellularity, granulocytic proliferation, and decreased erythropoiesis
    • WHO criteria for CML/PV/ET/MDS not met 
    • Positive for JAK 2/CALR/MPL

or presence of another clonal marker  (By cytogenetics or NGS panel for myeloid neoplasms) 

Or

Absence of minor reactive bone marrow reticulin fibrosis (Due to conditions such as infection, autoimmune disorder or other chronic inflammatoryconditions, hairy cell leukaemia or another lymphoid neoplasm, metastatic malignancy)

• Minor criteria: 
  • Anaemia not attributed to a comorbid condition
  • Leucocytosis- >11,000/cmm
  • Palpable splenomegaly
  • LDH level above the upper limit of the institutional reference range
• Overt Fibrotic stage: All 3 major and at least 1 minor criteria (Minor criteria must be metwhich is confirmed in 2 consecutive determinations)
  • Major: 
    • Megakaryocytic proliferation and atypia, accompanied by reticulin fibrosis grades 2 or 3 
    • WHO criteria for CML/PV/ET/MDS not met 
    • Positive for JAK 2/CALR/MPL or presence of another clonal marker  (By cytogenetics or NGS panel for myeloid neoplasms) or absence of reactive myelofibrosis
  • Minor: 
    • Anemia not attributable to comorbid condition 
    • Leucocytosis- >11,000/cmm 
    • Palpable splenomegaly
    • Raised LDH 
    • Leukoerythroblastosis 

Prognosis: 

International Prognostic Scoring System (IPSS) 

 
Dynamic International Prognostic Scoring System (DIPSS) 

DIPSS-PLUS Scoring system 

* Unfavorablekaryotypes include: Complex karyotype or trisomy 8, 7/7q-, i(17q), 5/5q-, 12p-, inv(3) or 11q23 rearrangements 

MIPSS70+ v2.0 is a prognostic scoring system

* Cytogenetics: 

• Very high risk (VHR): Single/multiple abnormalities of -7, i(17q), inv(3)/3q21, 12p-/12p11.2, 11q-/11q23, or other autosomal trisomies not including + 8/ + 9 (eg, +21, +19).
• Favorable: Normal karyotype or sole abnormalities of 13q-, +9, 20q-, chromosome 1 translocation/duplication or sex chromosome abnormality including -Y.
• Unfavorable: All other abnormalities.

Overall mean survival is 3-5 years 

Pretreatment Work-up: 

• History : Symptom burden 
• Examination 
• Spleen: 
• WHO P. S. 
• BSA 
• BMA and Bx 
• Reticulin/ Trichrome 
• Hemoglobin 
• TLC, DLC 
• Platelet count 
• Peripheral smear 
• LFT- Bili- T/D      SGPT:          SGOT: Albumin:    Globulin: 
• Creatinine 
• Uric acid 
• Electrolytes : Na:      K:       Ca: Mg:              PO4: 
• LDH 
• HIV 
• HBsAg 
• HCV 
• Cytogenetics 
• BCR-ABL1 
• JAK 2 
• CAL-R 
• MPL-1 
• HLA Typing for transplant candidate 
• Prognostic score
• Chemotherapy consent after informing about disease, prognosis, cost of therapy, side effects, hygiene, food and contraception
• Tumor board meeting and decision
• Attach supportive care drug sheet
• Inform primary care physician

Treatment Plan: 

Low risk patients with low platelet counts or complex cytogenetics may be evaluated for Allo-SCT.

For assessment of symptom burden refer to Myeloproliferative Disorders- Introduction- Click Here

Myelofibrosis with accelerated phase/ MF with blast phase

• Median survival- <1year 
• Transplant candidate: Induce remission with hypomethylating agents/ intensive chemotherapy (such as 7+3 induction). This should be followed by allogeneic SCT in CR1. 
• Not a transplant candidate:  
  • Hypomethylating agents- Azacytidine, Decitabine with/without JAK inhibitors
  • Low intensity induction chemotherapy 

Response Criteria (Benefit must last for >12 weeks to qualify as response): 

Complete response: 

• Bone marrow- Normocellular for age with <5% blasts and ≤ Grade 1 fibrosis 
• Peripheral blood- Hb>10gm/dL, ANC >1000/cmm, Platelet count >1lac/cmm, <2% immature myeloid cells (Includes blasts, promyelocytes, myelocytes and metamyelocytes) 
• Complete resolution of symptoms and non palpable spleen and liver. 

Partial response: 

• Same as above but one of either of BM or Peripheral blood criteria are fulfilled along with clinical criteria. 

For Ruxolitinib, to assess symptom improvement, Myeloproliferative Neoplasm Symptom Assessment Form is used, which is available here. 

About Each Modality of Treatment: 

• Ruxolitinib  (JAK 2 inhibitor) 
  • 15mg- BD. If there is pre-existing anemia/ thrombocytopenia, start with a dose of 5mg- BD. 
  • It is useful even in patients without JAK 2 mutation.
  • Avoid in patients with platelet counts <50,000/cmm. 
  • Hold if there is worsening of anemia, thrombocytopenia. Restart with lower dose and use EPO/Darbapoietin and/or danazol. 
  • Useful in reducing splenomegaly and and myelofibrosis related symptoms such as pruritis. 
  • Shown to decrease hepatomegaly and portal hypertensionwhich occurs because of myelofibrosis. 
  • High risk of HBV reactivation. Hence HBV testing and prophylaxis if required must be given. 
  • There is high risk of reactivation of tuberculosis, hence take appropriate measures. 
  • Stop if there is no benefit after 3 months or side effects are not tolerable. 
  • Taper the dose over 10 days while stopping with coverage of steroids 
• Interferons- Very less clinical effect 
• Hydroxyurea  
  • Up to 1gm/day 
  • Compared to other MPN, marrow tolerance to chemotherapy is low 
  • Given for cytoreduction, if there is leukocytosis or thrombocytosis 
  • Helps to decrease constitutional symptoms and organomegaly as well 
  • Benefit is seen in 8-10 weeks of treatment 
• Erythropoiesis stimulating agents 
  • Inj. Erythropoietin- 10,000 units- 3 times a week 
  • Inj. Darbepoetin- 150microgm- weekly 
• Androgens -  
  • Danazol – 400 – 600 mg/day or  Oxymetholone – 200 mg – oral – OD 
  • Help to increase erythropoiesis 
  • 1/3 rd patients respond 
  • Continue for minimum of 6 months before evaluating response 
  • Continue for 6 more months in those patients who respond, then titrate the dose to minimum to maintain response 
  • Screen for prostate cancer in men 
  • Monitor LFT 
• Thalidomide/Lenalidomide with prednisolone 
  • Thalidomide- 50mg- OD or Lenalidomide 10mg- OD for 3 months 
  • Prednisolone-  
    • 0.5 mg/kg/day- first month 
    • 0.25 mg/kg/day- Second month 
    • 0.125 mg/kg/day- Third month 
  • If response after 3 months of therapy- Continue thalidomide for next 3 months 
  • Presence of del 5q is associated with better response rates with lenalidomide 
• Allogeneic bone marrow transplant: 
  • Only therapy with a chance of cure 
  • Overall outcome is poor due to defect in microenvironment (fibrosis) and splenomegaly.
  • Indications: 
    • Intermediate 2 and High risk patients 
    • Intermediate 1 patients with low platelet counts and complex cytogenetics 
    • NGS showing "higher risk" mutations 
  • Consider following before selecting patient for BMT: 
    • Age 
    • Performance score 
    • Major co-morbid conditions 
    • Psychosocial status 
    • Patient preference 
    • Availability of care giver 
    • If patient is in blast crisis, bridging therapy is necessary to decrease the blast percentage to acceptable levels 
  • Splenectomy prior to transplant leads to earlier engraftment, without impact on overall survival or graft failure. Hence not recommended routinely. 
  • Better results in patients receiving<20 blood transfusions 
  • Usually RIC regimens are used. 
  • Ruxolitinib may be given for some time to improve general condition 
  • 5 year overall survival-30%- 68% 
  • TRM at 1 year- 16-48% 
  • Post transplant monitoring- JAK2 PCR. Molecular relapse to be treated with donor lymphocyte infusions. 

Supportive Care: 

• Supportive PRBC and platelet transfusions
  • Use leucoreduced products in prospective transplant candidate 
  • Tranexamic acid, if bleeding is refractory to transfusions 
  • Iron chelation after 20 transfusions 
• Prophylactic antibiotics if there are recurrent infections. G-CSF should be used with caution, due to risk of splenic rupture 
• Folic acid 5mg- OD 
• Aspirin- 75mg- OD - If there is thrombocytosis 
• Allopurinol if there is hyperuricemia 
• Masses of extramedullary hematopoiesis: Local radiation 
• Severe bone pain-  
  • Etidronate- 6mg/kg/day on alternate months 
  • Radiation can be used 
• Portosystemic shunt surgery:  
  • If there is gastro-esophageal variceal bleeding or if there is refractory ascites
  • If portal hypertension is due to increased flow from spleen to liver- Splenectomy is the treatment of choice 
  • If portal hypertension is due to intrahepatic block or hepatic vein thrombosis- Splenorenal shunt or TIPSS is the treatment of choice. 

Other Treatment Options: 

• Low dose Melphalan- 2.5mg- Thrice a week 
• Splenectomy: 
  • High risk of serious peri-operative complications such as bleeding, thrombosis and infections 
  • It is difficult as spleen is adherent to neighboringserosal surfaces and organs 
  • With best centers morbidity and mortality are 31% and 9% respectively 
  • Indications include severe thrombocytopenia  and very high transfusion requirements 
  • Laparoscopic splenectomy is not advised 
  • Long term penicillin prophylaxis has to be given 
• Splenic irradiation: 
  • Useful especially in case of painful splenomegaly 
  • Platelet count must be >50,000/cmm prior to radiation 
  • Can lead to severe cytopenia 
  • Used for patients who are not fit for splenectomy 
• Etanercept 
  • 25mg- SC- Twice weekly 
  • Associated with improvement in constitutional symptoms such as weight loss, night sweats, fatigue, fever etc 
• Ciclosporine 
  • Achieve trough levels of 100-200ng/ml 
  • Useful in patients with immune disorders (DCT/ ANA positive patients) 

Special Situations: 

• Pregnancy: 
  • Similar to management of essential thrombocythemia with pregnancy
• Children: 
  • Following must be ruled out before making diagnosis of PMF 
    • Acute panmyelosis with myelofibrosis 
    • Acute megakaryocytic leukemia 
    • Autoimmune disorders, NK cell proliferations 
    • Familial cases of infantile myelofibrosis 
    • Causes of secondary myelofibrosis such as rickets 
    • Hypocellular MDS 
  • Many cases presenting in infancy eventually "burn out" with spontaneous erythropoietic recovery, occurring as early as 2-3 years after diagnosis 
  • Curative option for "true" PMF- Allo SCT 
  • Trial of steroids should be considered, once AMKL and rickets have been excluded. 

Secondary myelofibrosis:

• Causes include
  • Tuberculosis
  • Histoplasmosis 
  • Metastatic bone marrow disease
  • Renal osteodystrophy 
  • Vitamin D deficiency (Rickets) 
  • Hypoparathyroidism 
  • Hyperparathyroidism 
  • Gray platelet syndrome 
  • Systemic lupus erythematosus 
  • Scleroderma 
  • Radiation exposure 
  • Osteopetrosis 
  • Paget disease 
  • Benzene exposure 
  • Thorotrast exposure 
  • Goucher disease 
  • Primary autoimmune myelofibrosis 
  • Other hematological malignancies: AML, ALL, HCL, HD, MDS, Myeloma, systemic mastocytosis, NHL 

Autoimmune myelofibrosis:

• 8 diagnostic criteria must be met
  • Grade 3 or 4 reticulin fibrosis 
  • Lack of clustered or atypical megakaryocytes 
  • Lack of dysplasia/ eosinophilia/ basophilia 
  • Lymphoid infiltration of marrow 
  • Lack of osteosclerosis 
  • Absent or mild splenomegaly 
  • Presence of autoantibodies 
  • Lack of disorders associated with PMF 

Figures: 

Figure 2.5.1 - Primary myelofibrosis- Prefibrotic phase- Peripheral smear

Figure 2.5.2- Primary myelofibrosis- Fibrotic phase- Peripheral smear

Figure 2.5.3 - Primary myelofibrosis- Fibrotic phase- Bone marrow biopsy

Figure 2.5.4- Primary myelofibrosis- Fibrotic phase- Bone marrow biopsy- Reticulin stain

Recent advances:

Addition of Navitoclax to Ruxolitinib improves overall outcome in patients with primary myelofibrosis 

Navitoclax is a BCL-X_L/BCL-2 inhibitor. This drug was evaluated in high risk myelofibrosis patients who had suboptimal response to ruxolitinib. There was significant decrease in splenic size, decrease in total symptom score and improvement of hemoglobin levels. Follow-up bone marrow biopsy showed significant decrease in BM fibrosis.  

https://doi.org/10.1200/JCO.21.02188 

Zinpentraxin alfa in myelofibrosis

Zinpentraxin alfa, a recombinant form of PTX-2, an antifibrotic protein, was studied in a phase II trial involving patients with myelofibrosis (MF). The trial included 27 patients who received zinpentraxin alfa either alone or with ruxolitinib. The primary endpoint, the overall response rate (ORR), was 33% at week 24. Some patients also experienced improvements in symptom scores and bone marrow fibrosis. Most adverse events were mild, with fatigue being the most common. Anemia and thrombocytopenia were infrequent, and serious treatment-related adverse events occurred in a small number of patients. Zinpentraxin alfa showed promise as a potential therapy for MF in this trial.

https://doi.org/10.3324/haematol.2022.282411

Pelabresib in Combination With Ruxolitinib in Naïve Myelofibrosis 

In a phase II study (MANIFEST), the combination of the bromodomain and extraterminal domain inhibitor (BETi) pelabresib with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis showed promising results. At 24 weeks, 68% of patients achieved a spleen volume reduction of ≥ 35%, and 56% achieved a total symptom score reduction of ≥ 50%. Additional benefits included improved hemoglobin levels, reduced fibrosis, and a reduction in JAK2V617F-mutant allele fraction. The combination therapy was generally well-tolerated, with thrombocytopenia and anemia being the most common grade 3 or 4 toxicities. 

https://doi.org/10.1200/JCO.22.01972 

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis 

The study aimed to compare outcomes of patients aged 70 or below with myelofibrosis (MF) in chronic phase who received upfront JAK inhibitor (JAKi) therapy versus upfront allogeneic hematopoietic cell transplantation (HCT) in dynamic international prognostic scoring system (DIPSS)-stratified categories. The results showed that, for the entire cohort, median overall survival (OS) was longer for patients who received JAKi compared to upfront HCT. In patients with intermediate-2 and high-risk disease, median OS was not significantly different between JAKi and HCT. The study suggests that a universal upfront HCT approach for higher-risk MF may not provide significant benefits. 

https://doi.org/10.1038/s41409-023-02146-6 

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis

The study analyzed outcomes of 346 CALR-mutated myelofibrosis (MF) patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) in 123 EBMT centers between 2005 and 2019. After a median follow-up of 40 months, the estimated overall survival (OS) rates at 1, 3, and 5 years were 81%, 71%, and 63%, respectively. Patients receiving busulfan-containing regimens achieved a 5-year OS rate of 71%. Non-relapse mortality (NRM) at 1, 3, and 5 years was 16%, 22%, and 26%, respectively, while the incidence of relapse/progression was 11%, 15%, and 17%, respectively. Older age correlated with worse OS, while primary MF and HLA-mismatched transplants had a near-to-significant trend to decreased OS. Comparative analysis between CALR- and JAK2-mutated MF patients revealed better OS, lower NRM, lower relapse, and improved graft-versus-host disease-free and relapse-free survival in CALR-mutated patients. 

https://doi.org/10.1038/s41409-023-02094-1

Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation

This study investigated the safety and efficacy of splenic irradiation before allogeneic hematopoietic cell transplantation (HCT) in patients with myelofibrosis who failed Janus kinase (JAK) inhibition. Among 59 patients, splenic irradiation led to significant spleen size reduction in 97% of cases, with a median decrease of 5.0 cm. The 3-year overall survival rate was 62%, and the 1-year non-relapse mortality was 26%. Splenic irradiation, when adjusted for confounders, was associated with significantly reduced relapse rates compared to immediate HCT or splenectomy, demonstrating its potential benefit in this patient population.

https://doi.org/10.1002/ajh.27252

Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis

This sub-analysis of SIMPLIFY-1 compared momelotinib and ruxolitinib in JAK inhibitor-naïve Japanese myelofibrosis patients. At 24 weeks, momelotinib showed a 50% spleen response rate (SRR) versus 44.4% with ruxolitinib. Total symptom score response was 33.3% for momelotinib and 0% for ruxolitinib, while transfusion independence rates were 83.3% and 44.4%, respectively. Momelotinib was well tolerated and reduced transfusion needs, with fewer grade 3/4 adverse events than ruxolitinib.

https://doi.org/10.1007/s12185-024-03822-z

Treatment of myelofibrosis with refractory anemia with luspatercept

In this retrospective study, 18 patients with refractory anemic myelofibrosis were treated with luspatercept for at least 9 weeks. Erythroid response was observed in 44.4% of patients at week 12, 30.8% at week 24, and 50% by the end of follow-up. Hemoglobin levels significantly improved at all time points, and adverse events were mild, affecting 16.7% of patients. The relapse rate was low, with only two patients relapsing and one progressing to acute myeloid leukemia. Luspatercept demonstrated good efficacy and safety in treating anemia in myelofibrosis patients.

https://doi.org/10.1007/s00277-024-05847-0

Autoimmune myelofibrosis: A Mayo Clinic series of 22 patients

In this study of 22 patients with autoimmune myelofibrosis (AIMF), 77% were female, with a median age of 45 years. Pancytopenia was present in 32%, and 59% required transfusions for anemia. Most patients (83%) had a history of autoimmune disease, and they were negative for JAK2, CALR, and MPL mutations. A complete response (CR), marked by resolution of cytopenias, was achieved in 74% of evaluable cases. First-line treatments included steroids alone or with immunosuppressants, cyclosporin, and mycophenolate, achieving CR in 54%, 50%, and 50% of cases, respectively. Rituximab as a salvage therapy was highly effective, with an 80% CR rate, offering a promising steroid-sparing option for AIMF

https://doi.org/10.1111/bjh.19499 

Momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients          

This real-world analysis of momelotinib in 60 myelofibrosis (MF) patients demonstrated significant improvements in anemia (84% hemoglobin rise), platelet counts (67%), and transfusion independence (21% within 4 weeks). Symptom relief occurred in 47% and spleen size reduced in 25% (median 6 weeks). Creatinine increases (17%) were manageable, and treatment discontinuation was rare (8% due to side effects). Momelotinib is effective and safe, even in heavily pre-treated cytopenic MF patients.

https://doi.org/10.1007/s00277-024-05908-4

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib

The FREEDOM2 trial evaluated fedratinib versus best available therapy (BAT) in patients with myelofibrosis relapsed, refractory, or intolerant to ruxolitinib. Among 201 treated patients, spleen volume reduction (SVR) ≥35% by cycle 6 was achieved in 36% of fedratinib-treated patients compared to 6% in the BAT group. Fedratinib was associated with higher rates of grade ≥3 adverse events (40% vs. 12%), primarily anemia and thrombocytopenia, but gastrointestinal side effects were manageable with prophylactic antiemetics and thiamine supplementation. These findings support fedratinib as a viable second-line therapy for patients with myelofibrosis post-ruxolitinib, with effective strategies to mitigate adverse effects.

https://doi.org/10.1016/S2352-3026(24)00212-6